Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

ELDN 11.06.2024

Full Press ReleaseSEC FilingsOur ELDN Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
  • 12.11.2024 - Targeting the CD40L Pathway to Improve Immunosuppression Therapy & Help Organ Transplants Last Longer
  • 11.26.2024 - Eledon Works Toward Potential T1D Treatment

Recent Filings

  • 01.13.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.20.2024 - 8-K Current report

IRVINE, Calif.,Nov. 06, 2024(GLOBE NEWSWIRE) --Eledon Pharmaceuticals, Inc.(“Eledon”) (Nasdaq: ELDN) today announced thatDavid-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcomingGuggenheim Securities Inaugural Healthcare Innovation ConferenceonWednesday, November 13, 2024, at1:30 p.m. ET(10:30 a.m. PT).

To register in advance for the presentation webcast, sign uphere.

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website athttps://ir.eledon.com/news-and-events/events.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine,California. For more information, please visit the Company’s website atwww.eledon.com.

Follow Eledon Pharmaceuticals on social media:LinkedIn;Twitter

Investor Contact:

Stephen JasperGilmartin Group(858) 525 2047stephen@gilmartinir.com

Media Contact:

Jenna UrbanBerry & Company Public Relations(212) 253 8881jurban@berrypr.com

Source: Eledon Pharmaceuticals

Primary Logo

Source: Eledon Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com